HCW Biologics Inc. (HCWB)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Why Is Penny Stock HCW Biologics Surging On Monday?
HCW Biologics Inc HCWB stock is trading higher during Monday premarket with a strong session volume of 10.03 million versus an average volume of 48.02K, as per data from Benzinga Pro.
HCW Biologics Inc. (HCWB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has HCW Biologics Inc. ever had a stock split?
HCW Biologics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Hing C. Wong CEO | NASDAQ (CM) Exchange | 40423R204 CUSIP |
| US Country | 36 Employees | - Last Dividend | 11 Apr 2025 Last Split | 20 Jul 2021 IPO Date |
Overview
HCW Biologics Inc. stands as a prominent clinical-stage biopharmaceutical company, centered on innovating and progressing novel immunotherapies aimed at chronic, low-grade inflammation, along with age-related diseases across the United States. With its inception in 2018, the company has firmly established its headquarters in Miramar, Florida. It underscores a dedicated pursuit towards addressing the complexities of chronic inflammation and age-associated disorders through cutting-edge immunotherapeutic strategies.
Products and Services
HCW9218: Esteemed as the lead product, HCW9218 is currently undergoing Phase 1 clinical trials targeting chemo-refractory/chemo-resistant solid tumors. This includes a spectrum of cancers such as pancreatic, ovarian, breast, prostate, and colorectal. Additionally, it has stepped into Phase 2 clinical trial, specifically for patients with metastatic advanced stage ovarian cancer, showcasing the company's dedication towards battling prolific and life-threatening cancers through innovative therapeutic approaches.
HCW9302: Focused on autoimmune and proinflammatory diseases, including alopecia areata, HCW9302 embodies HCW Biologics Inc.'s commitment to broadening its therapeutic range. By addressing diseases like alopecia areata, the company underlines its dedication to combatting conditions that profoundly affect individuals' quality of life, leveraging the potential of immunotherapy.
HCW9201: Representing the company's ventures into cell-based therapies, HCW9201 is a groundbreaking treatment currently in Phase I clinical trials aimed at patients with relapsed/refractory acute myelogenous leukemia. This initiative signifies a novel approach in treating such a severe form of leukemia, emphasizing personalized therapy options for those battling this challenging condition.
HCW9206: As an innovative injectable immunotherapeutic, HCW9206 is designed for use as an adjuvant in adoptive cell therapy for cancer treatment. This development reflects HCW Biologics Inc.'s ongoing efforts to enhance and support cancer treatment regimes, underlining the potential of immunotherapy in augmenting conventional cancer treatments and improving patient outcomes.
